MedTrace Logo

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

NCT04861090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 207

Last updated 2023-01-13

No results posted yet for this study

Summary

The main aims of this study are to learn how many people with HAE Type I or Type II are attack-free when treated with lanadelumab in real life. This includes the number of people that are attack-free when lanadelumab is given every 2 and every 4 weeks.

This study is about collecting existing data only; participants will not receive lanadelumab as part of this study. No new information will be collected during this study. Only data already available at the participant's doctor's office will be reviewed and collected for this study.

Participants do not need to visit their doctor in addition to their normal visits.

Conditions

  • Hereditary Angioedema (HAE)

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Austria
  • France
  • Germany
  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04861090 on ClinicalTrials.gov